Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $126.63 Analyst target: $141.61 Upside: 11.83%
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.